secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2023-10-27T23:59:59+00:00
Accession:  0001493152-23-038523
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics implements 1-for-25 reverse stock split to meet Nasdaq minimum bid price
--------------------------------------------------------------------------------

- Reverse stock split at 1:25 ratio effective October 25, 2023; shares reduced from ~29.9M to ~1.2M.
- Common stock began trading on post-split basis on Nasdaq under same ticker VVOS on October 27, 2023.
- No fractional shares issued; fractional shares rounded up to nearest whole share.
- Split approved by board under stockholder authority granted at 2023 Annual Meeting on September 22, 2023.
- Company aims to satisfy $1.00 minimum bid price requirement for continued Nasdaq listing under Rule 5550(a)(2).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223038523/0001493152-23-038523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223038523/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-038523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer